Peter Bains, executive director of Syngen International Ltd
The Biocon contract manufacturing arm, Syngent International, has registered a 3 percent year -on -year decrease in profits after taxes (PAT) to 183 million rupees for the quarter of March, below ₹ 189 million rupees in the same period last year. However, the revenues for the quarter crossed the milestone of ₹ 1,000 million rupees for the first time, reaching ₹ 1,018 million rupees. This marks a sequential growth of 8 percent and a 11 percent increase in an year -on -year base.
According to Peter Bains, managing director and CEO, income growth was promoted by strong performance in the Biologics CDMO business, backed by commercial manufacturing and the addition of new development projects. “After a silenced first half, driven by a sectoral recession in the financing of the biotechnology of the United States, it encourages us to see the return to growth in the second half of the year,” Bains said.
By recognizing global uncertainties, he added: “We hope that the commercial impulse will continue with a construction of pipes in small and large molecules, backed by new pilot programs and the conversion of existing pilots in the discovery services.”
Looking towards fiscal year 26, Syngen expects a underlying growth of income in the first adolescents, reflecting the broad base impulse between research, development and manufacturing services. However, it is likely that the growth of the informed income is in the average digits, after adjusting the inventory balance in the commercial manufacture of large molecules at the client level.
The company’s shares closed to 754.00, at 2.52 percent in EEB. (With internal bloc tickets Rohan das)
Posted on April 23, 2025